Just one year ago our First International Symposium on "Renthiver Nodules: Significance to Human Risk", was convened in Reston, VA. The topic of that meeting was rodent liver nodules and their significance to human cancer risk. The Society was extremely gratified by a favorable post-meeting response and consider this a fitting tribute to the successful integration of applied and basic research concepts in toxicologic pathology by an outstanding group of speakers. The proceedings of this meeting will be published and available for distribution very soon.
One of the major issues discussed in last year's meeting was the reversibility or lack of progression of hepatocellular lesions described as neoplastic nodules. Surprisingly, the majority of the participating experts recognized reversibility of these lesions in a very high percentage of the animal experiments which had demonstrated chemical or nonchemical nodule induction. On the other hand, it was equally unanimous that while rare, incidences of frank neoplastic cellular changes were found within well defined liver nodules. Hence, the probability that an experimentally induced liver nodule in aged rodents represents a true carcinogenic response appears to be very low, but there is no morphologic or biochemical basis for differentiating these lesions from the isolated instances which may eventually manifest themselves as true neoplasms. The majority of highly potent rodent carcinogens induce specific neoplastic lesions in relatively short periods of time-usually less than one year. Likewise, these induced proliferative cellular This Symposium section will be continued in Volume 11, Number 2.1983.
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reactions assume autonomous characteristics early on, so that removal of the carcinogenic stimulus does not influence the ultimate growth and development of the neoplasm. It would then seem plausible that the concept of cellular autonomy would represent a reasonable means of differentiating true preneoplastic or induced cellular proliferation from toxicologically stimulated chronic, reactive hyperplasia. But how do you identify and quantitate autonomy in a standard two year rodent bioassay?
One method suggested by a paper presented last year was the "stop segment" or periodic recovery-phase experiment. In this protocol, several time periods are selected when a small group of animals are sacrificed while a larger group are withdrawn from treatment and allowed to remain in the study until the terminal two year sacrifice. Assuming that an increased tumor incidence was found in the animals treated continuously for two years, then the histopathological evaluation of the suspect organs or tissues from the various recovery groups could leave valuable interpretive significance relative to latency, pre-neoplasia and autonomy.
So we are here to discuss the design of carcinogenicity studies. Our ultimate goal is to examine the latest options available to us to be able to increase the pathologist's ability to understand the biological characteristics of proliferative lesions. Within the context of this meeting, we will take the standard rodent bioassay protocol and examine ways of deriving more information that what we are currently being able to obtain. First, we can see if there are new experimental techniques that will help us reach this goal. Second, we will address the concept of cellular autonomy and ask the question: Will the inclusion of recovery groups help differentiate hyperplastic proliferation from oncogenic lesions?
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Finally, the symposium will close with a panel meeting of primarily regulatory scientists who are involved in these decisions, and we will address, hopefully, the role that autonomy might play and whether it is realistic within their environment to use this for future interpretation of pathology data. I know you will enjoy these presentations and I hope that we can have the same type of participation from the audience that we had last year.
